Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations.
Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations.
复制标题
DOI:
10.1007/s11060-017-2458-0
复制
发表时间:
2017-09
影响因子:
3.9
通讯作者:
Ahmed MM
中科院分区:
文献类型:
--
作者:
Kunos CA;Galanis E;Buchsbaum J;Shi Q;Strauss LC;Coleman CN;Ahmed MM
Glioblastoma is an aggressive disease characterized by moderate initial response rates to first-line radiation-chemotherapy intervention followed by low poor response rates to second-line intervention. This article discusses novel strategic platforms for the development of radiation-investigational agent combination clinical trials for primary and recurrent glioblastoma in a NCI-NCTN settings with simultaneous analysis of challenges in the drug development process.
登录
查看更多内容
影响因子:
15.9
作者:
Hutterer, Markus;Nowosielski, Martha;Stockhammer, Guenther
通讯作者:
Stockhammer, Guenther
影响因子:
4.1
作者:
LEVIN, VA;WILSON, CB;IRWIN, L
通讯作者:
IRWIN, L
影响因子:
158.5
作者:
Hegi, ME;Diserens, A;Stupp, R
通讯作者:
Stupp, R
DOI:
10.1158/1078-0432.ccr-13-0708
发表时间:
2013-09-01
期刊:
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子:
--
作者:
Galanis E;Anderson SK;Lafky JM;Uhm JH;Giannini C;Kumar SK;Kimlinger TK;Northfelt DW;Flynn PJ;Jaeckle KA;Kaufmann TJ;Buckner JC
通讯作者:
Buckner JC
影响因子:
15.9
作者:
Ma, Daniel J.;Galanis, Evanthia;Sarkaria, Jann N.
通讯作者:
Sarkaria, Jann N.